Advances in targeting cyclic nucleotide phosphodiesterases

[1]  Clint L. Miller,et al.  Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. , 2013, Journal of molecular and cellular cardiology.

[2]  M. Cazzola,et al.  Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[3]  A. Gore.  The next century of endocrinology. , 2013, Endocrinology.

[4]  N. Raghavachari,et al.  A role for phosphodiesterase 3B in acquisition of brown fat characteristics by white adipose tissue in male mice. , 2013, Endocrinology.

[5]  K. Krobert,et al.  PDE3, but not PDE4, reduces β1‐ and β2‐adrenoceptor‐mediated inotropic and lusitropic effects in failing ventricle from metoprolol‐treated patients , 2013, British journal of pharmacology.

[6]  M. Wittmann,et al.  Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases , 2013, Dermatology and Therapy.

[7]  M. Schummer,et al.  Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers , 2013, Proceedings of the National Academy of Sciences.

[8]  W. Kolch,et al.  Phosphodiesterase-8A binds to and regulates Raf-1 kinase , 2013, Proceedings of the National Academy of Sciences.

[9]  G. Baillie,et al.  Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. , 2013, Future medicinal chemistry.

[10]  P. Barnes.  Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. , 2013, The Journal of allergy and clinical immunology.

[11]  W. Seeger,et al.  Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF , 2013, Oncogene.

[12]  Dave Singh,et al.  Novel anti-inflammatory agents in COPD: targeting lung and systemic inflammation. , 2013, Current drug targets.

[13]  W. Shen,et al.  Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart , 2013, Circulation research.

[14]  M. Trautmann,et al.  Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 , 2013, Expert opinion on drug discovery.

[15]  C. Lugnier,et al.  NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production. , 2013, Canadian journal of physiology and pharmacology.

[16]  D. Craik,et al.  The Future of Peptide‐based Drugs , 2013, Chemical biology & drug design.

[17]  E. Hu,et al.  Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux. , 2012, Bioorganic & medicinal chemistry letters.

[18]  B. Beghé,et al.  Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice. , 2012, Respiratory medicine.

[19]  A. E. van den Bosch,et al.  The usefulness of brain natriuretic peptide in complex congenital heart disease: a systematic review. , 2012, Journal of the American College of Cardiology.

[20]  S. Bickston,et al.  Tetomilast: new promise for phosphodiesterase-4 inhibitors? , 2012, Expert opinion on investigational drugs.

[21]  Laura McDowell,et al.  Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. , 2012, Journal of medicinal chemistry.

[22]  Yi Liu,et al.  Prolyl hydroxylase domain protein 2 regulates the intracellular cyclic AMP level in cardiomyocytes through its interaction with phosphodiesterase 4D. , 2012, Biochemical and biophysical research communications.

[23]  Zhe Li,et al.  Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. , 2012, Journal of medicinal chemistry.

[24]  Angela M. Lane,et al.  Protein Kinase G Iα Inhibits Pressure Overload–Induced Cardiac Remodeling and Is Required for the Cardioprotective Effect of Sildenafil In Vivo , 2012, Journal of the American Heart Association.

[25]  D. Storm,et al.  Inactivation of Pde8b enhances memory, motor performance, and protects against age‐induced motor coordination decay , 2012, Genes, brain, and behavior.

[26]  J. Dyck,et al.  Resveratrol as a calorie restriction mimetic: therapeutic implications. , 2012, Trends in cell biology.

[27]  Mahesh Y. Pawar,et al.  Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model. , 2012, Bioorganic & medicinal chemistry letters.

[28]  W. Catterall,et al.  Phosphoinositide 3-Kinase &ggr; Protects Against Catecholamine-Induced Ventricular Arrhythmia Through Protein Kinase A–Mediated Regulation of Distinct Phosphodiesterases , 2012, Circulation.

[29]  R. Onrust,et al.  Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. , 2012, Bioorganic & medicinal chemistry letters.

[30]  M. Zaccolo,et al.  PKA and PDE4D3 anchoring to AKAP9 provides distinct regulation of cAMP signals at the centrosome , 2012, The Journal of cell biology.

[31]  H. Inoue,et al.  Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. , 2012, The Journal of urology.

[32]  F. Faucz,et al.  Identification of novel genetic variants in phosphodiesterase 8B ( PDE8B ), a cAMP‐specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours , 2012, Clinical endocrinology.

[33]  D. Kass,et al.  Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling , 2012, Circulation.

[34]  Dong-mei Jin,et al.  Cilostazol-Based Triple Antiplatelet Therapy Compared to Dual Antiplatelet Therapy in Patients with Coronary Stent Implantation: A Meta-Analysis of 5,821 Patients , 2012, Cardiology.

[35]  D. Kass.  Cardiac Role of Cyclic-GMP Hydrolyzing Phosphodiesterase Type 5: From Experimental Models to Clinical Trials , 2012, Current Heart Failure Reports.

[36]  K. Rabe,et al.  Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. , 2012, The Journal of clinical endocrinology and metabolism.

[37]  M. Conti,et al.  Cyclic adenosine monophosphate phosphodiesterase type 4 protects against atrial arrhythmias. , 2012, Journal of the American College of Cardiology.

[38]  M. Marletta,et al.  Structure and regulation of soluble guanylate cyclase. , 2012, Annual review of biochemistry.

[39]  Domenico Spina,et al.  Selective PDE inhibitors as novel treatments for respiratory diseases. , 2012, Current opinion in pharmacology.

[40]  M. Aghaei,et al.  Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF‐7 and MDA‐MB‐468 , 2012, Cell proliferation.

[41]  Y. Itzhak,et al.  The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice , 2012, Journal of psychopharmacology.

[42]  D. Hwang,et al.  Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. , 2012, Journal of medicinal chemistry.

[43]  N. Sugimoto,et al.  Phosphodiesterase Inhibitors Suppress Lactobacillus casei Cell-Wall-Induced NF-κB and MAPK Activations and Cell Proliferation through Protein Kinase A—or Exchange Protein Activated by cAMP-Dependent Signal Pathway , 2012, TheScientificWorldJournal.

[44]  A. Finn,et al.  Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics , 2012, Clinical cardiology.

[45]  F. Hakuno,et al.  Phosphatidylinositol 3-kinase-binding protein, PI3KAP/XB130, is required for cAMP-induced amplification of IGF mitogenic activity in FRTL-5 thyroid cells. , 2012, Molecular endocrinology.

[46]  W. Greenlee,et al.  The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. , 2012, Bioorganic & medicinal chemistry letters.

[47]  F. Menniti,et al.  PDE Inhibition and cognition enhancement , 2012, Expert opinion on therapeutic patents.

[48]  J. Beavo,et al.  cAMP-Specific Phosphodiesterases 8A and 8B, Essential Regulators of Leydig Cell Steroidogenesis , 2012, Molecular Pharmacology.

[49]  Jianhua Cao,et al.  Discovery of oxazole-based PDE4 inhibitors with picomolar potency. , 2012, Bioorganic & medicinal chemistry letters.

[50]  N. Pham,et al.  Roflumilast: A Novel Treatment for Chronic Obstructive Pulmonary Disease , 2012, The Annals of pharmacotherapy.

[51]  C. Enroth,et al.  Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[52]  C. Lugnier,et al.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments , 2012, British journal of pharmacology.

[53]  S. Harding,et al.  Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. , 2012, Life sciences.

[54]  H. Ke,et al.  Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases , 2012, Cell.

[55]  K. Dodge-Kafka,et al.  AKAPs: the architectural underpinnings of local cAMP signaling. , 2012, Journal of molecular and cellular cardiology.

[56]  M. Zaccolo,et al.  cGMP-cAMP interplay in cardiac myocytes: a local affair with far-reaching consequences for heart function. , 2012, Biochemical Society transactions.

[57]  J. Bourguignon,et al.  Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor , 2012, PloS one.

[58]  S. Chan,et al.  PDE1 isozymes, key regulators of pathological vascular remodeling. , 2011, Current opinion in pharmacology.

[59]  M. Conti.  Phosphodiesterases and regulation of female reproductive function. , 2011, Current opinion in pharmacology.

[60]  J. Beavo,et al.  The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. , 2011, Current opinion in pharmacology.

[61]  O. Wever-Pinzon,et al.  PDE3 inhibition in dilated cardiomyopathy. , 2011, Current opinion in pharmacology.

[62]  C. Stratakis,et al.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. , 2011, Current opinion in pharmacology.

[63]  J. Corbin,et al.  PDE5 inhibitors: targeting erectile dysfunction in diabetics. , 2011, Current opinion in pharmacology.

[64]  C. Lugnier.  PDE inhibitors: a new approach to treat metabolic syndrome? , 2011, Current opinion in pharmacology.

[65]  D. Maurice.  Subcellular signaling in the endothelium: cyclic nucleotides take their place. , 2011, Current opinion in pharmacology.

[66]  Clint L. Miller,et al.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart , 2011, Basic Research in Cardiology.

[67]  M. Conti,et al.  Phosphodiesterase 4D Regulates Baseline Sarcoplasmic Reticulum Ca2+ Release and Cardiac Contractility, Independently of L-Type Ca2+ Current , 2011, Circulation research.

[68]  U. Egerland,et al.  Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. , 2011, Journal of medicinal chemistry.

[69]  Khawla Abu samra,et al.  Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. , 2011, The journal of sexual medicine.

[70]  M. Nishida,et al.  Cilostazol Suppresses Angiotensin II–Induced Vasoconstriction via Protein Kinase A–Mediated Phosphorylation of the Transient Receptor Potential Canonical 6 Channel , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[71]  M. Zaccolo,et al.  Plasma Membrane Calcium Pump (PMCA4)-Neuronal Nitric-oxide Synthase Complex Regulates Cardiac Contractility through Modulation of a Compartmentalized Cyclic Nucleotide Microdomain* , 2011, The Journal of Biological Chemistry.

[72]  Lynn A. Hyde,et al.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.

[73]  Andrew W. Greaves,et al.  Cyclic nucleotide phosphodiesterase 7B mRNA: An unfavorable characteristic in chronic lymphocytic leukemia , 2011, International journal of cancer.

[74]  T. Pastinen,et al.  Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients , 2011, Mediators of inflammation.

[75]  P. Barnes.  Biochemical Basis of Asthma Therapy* , 2011, The Journal of Biological Chemistry.

[76]  W. Catterall,et al.  Phosphodiesterase 4B in the cardiac L-type Ca²⁺ channel complex regulates Ca²⁺ current and protects against ventricular arrhythmias in mice. , 2011, The Journal of clinical investigation.

[77]  C. Steegborn,et al.  A Phosphodiesterase 2A Isoform Localized to Mitochondria Regulates Respiration* , 2011, The Journal of Biological Chemistry.

[78]  P. Igarashi,et al.  Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases , 2011, Proceedings of the National Academy of Sciences.

[79]  J. Clarke,et al.  What is a systematic review? , 2011, Evidence Based Nursing.

[80]  K. Fennell,et al.  Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. , 2011, Journal of medicinal chemistry.

[81]  Zhe-Sheng Chen,et al.  Roles of sildenafil in enhancing drug sensitivity in cancer. , 2011, Cancer research.

[82]  V. Manganiello,et al.  Phosphodiesterase 3A (PDE3A) Deletion Suppresses Proliferation of Cultured Murine Vascular Smooth Muscle Cells (VSMCs) via Inhibition of Mitogen-activated Protein Kinase (MAPK) Signaling and Alterations in Critical Cell Cycle Regulatory Proteins* , 2011, The Journal of Biological Chemistry.

[83]  K. Rabe.  Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease , 2011, British journal of pharmacology.

[84]  M. Zaccolo,et al.  Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes. , 2011, Journal of molecular and cellular cardiology.

[85]  F. Faucz,et al.  Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. , 2011, The Journal of clinical endocrinology and metabolism.

[86]  M. Zaccolo,et al.  cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes , 2011, Circulation research.

[87]  S. Bates,et al.  Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. , 2011, Cancer research.

[88]  C. Stratakis,et al.  How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues? , 2011, Molecular and Cellular Endocrinology.

[89]  S. Heymans,et al.  Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. , 2011, Molecular cell.

[90]  Richard Graham Knowles,et al.  GSK256066, an Exceptionally High-Affinity and Selective Inhibitor of Phosphodiesterase 4 Suitable for Administration by Inhalation: In Vitro, Kinetic, and In Vivo Characterization , 2011, Journal of Pharmacology and Experimental Therapeutics.

[91]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[92]  L. Potter.  Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. , 2011, Pharmacology & therapeutics.

[93]  M. Zaccolo,et al.  A Phosphodiesterase 3B-based Signaling Complex Integrates Exchange Protein Activated by cAMP 1 and Phosphatidylinositol 3-Kinase Signals in Human Arterial Endothelial Cells* , 2011, The Journal of Biological Chemistry.

[94]  R. D'Hooge,et al.  Impaired appetitively as well as aversively motivated behaviors and learning in PDE10A-deficient mice suggest a role for striatal signaling in evaluative salience attribution , 2011, Neurobiology of Learning and Memory.

[95]  Clint L. Miller,et al.  Cyclic Nucleotide Phosphodiesterase 1 Regulates Lysosome-Dependent Type I Collagen Protein Degradation in Vascular Smooth Muscle Cells , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[96]  C. Roehrborn,et al.  Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action , 2011, Neurourology and urodynamics.

[97]  N. Chattipakorn,et al.  Effects of cilostazol in the heart , 2011, Journal of cardiovascular medicine.

[98]  C. J. Schmidt,et al.  Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[99]  P. Schmieder,et al.  Small Molecule AKAP-Protein Kinase A (PKA) Interaction Disruptors That Activate PKA Interfere with Compartmentalized cAMP Signaling in Cardiac Myocytes , 2010, The Journal of Biological Chemistry.

[100]  M. Bruss,et al.  Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma. , 2010, The Journal of allergy and clinical immunology.

[101]  R. Fischmeister,et al.  Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes , 2010, Circulation research.

[102]  J. Beavo,et al.  Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy , 2010, Proceedings of the National Academy of Sciences.

[103]  G. Bernardi,et al.  Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease , 2010, PloS one.

[104]  I. Adcock,et al.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[105]  G. Baillie,et al.  p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. , 2010, Cellular signalling.

[106]  H. Ke,et al.  Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain* , 2010, The Journal of Biological Chemistry.

[107]  M. Houslay,et al.  Cyclic AMP Controls mTOR through Regulation of the Dynamic Interaction between Rheb and Phosphodiesterase 4D , 2010, Molecular and Cellular Biology.

[108]  G. Baillie,et al.  Cyclic AMP Phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a Vascular Endothelial Cadherin (VE-Cad)-based Signaling Complex and Controls cAMP-mediated Vascular Permeability* , 2010, The Journal of Biological Chemistry.

[109]  J. Beavo,et al.  Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. , 2010, Journal of molecular and cellular cardiology.

[110]  D. Cooper,et al.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex , 2010, The EMBO journal.

[111]  Han-Ting Zhang,et al.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25–35 or Aβ1–40 peptide in rats , 2010, Psychopharmacology.

[112]  K. Anderson,et al.  A Complex between FAK, RACK1, and PDE4D5 Controls Spreading Initiation and Cancer Cell Polarity , 2010, Current Biology.

[113]  Y. Yamasaki,et al.  The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial , 2010, Circulation.

[114]  John D. Scott,et al.  Signal integration through blending, bolstering and bifurcating of intracellular information , 2010, Nature Structural &Molecular Biology.

[115]  Christian Grunwald,et al.  Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. , 2010, Journal of medicinal chemistry.

[116]  W. Seeger,et al.  Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling , 2010, PloS one.

[117]  T. Comery,et al.  Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes , 2010, Proceedings of the National Academy of Sciences.

[118]  J. Wine,et al.  Compartmentalized Cyclic Adenosine 3′,5′-Monophosphate at the Plasma Membrane Clusters PDE3A and Cystic Fibrosis Transmembrane Conductance Regulator into Microdomains , 2010, Molecular biology of the cell.

[119]  Dave Singh,et al.  The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma , 2010, Respiratory research.

[120]  C. Lugnier,et al.  Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. , 2010, Current pharmaceutical design.

[121]  A. Nairn,et al.  cAMP-stimulated Protein Phosphatase 2A Activity Associated with Muscle A Kinase-anchoring Protein (mAKAP) Signaling Complexes Inhibits the Phosphorylation and Activity of the cAMP-specific Phosphodiesterase PDE4D3* , 2010, The Journal of Biological Chemistry.

[122]  M. Houslay,et al.  Putting the lid on phosphodiesterase 4 , 2010, Nature Biotechnology.

[123]  Timothy Hagen,et al.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety , 2010, Nature Biotechnology.

[124]  S. Pullamsetti,et al.  Targeting cancer with phosphodiesterase inhibitors , 2010, Expert opinion on investigational drugs.

[125]  S. Archer,et al.  Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. , 2009, The New England journal of medicine.

[126]  T. Comery,et al.  Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia , 2009, Journal of Pharmacology and Experimental Therapeutics.

[127]  K. Fennell,et al.  Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct , 2009, Proceedings of the National Academy of Sciences.

[128]  Y. Xiang,et al.  Differential Association of Phosphodiesterase 4D Isoforms with β2-Adrenoceptor in Cardiac Myocytes* , 2009, The Journal of Biological Chemistry.

[129]  S. P. Bhatnagar,et al.  A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. , 2009, Bioorganic & medicinal chemistry.

[130]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[131]  H. Gurm,et al.  Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[132]  G. Zoidl,et al.  Dual Acylation of PDE2A Splice Variant 3 , 2009, The Journal of Biological Chemistry.

[133]  Spiros Liras,et al.  Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. , 2009, Journal of medicinal chemistry.

[134]  Brian Evans,et al.  Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode. , 2009, Bioorganic & medicinal chemistry.

[135]  N. Press,et al.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease , 2009, British journal of pharmacology.

[136]  J. Flier,et al.  Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. , 2009, Endocrinology.

[137]  W. Zavadoski,et al.  The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. , 2009, Bioorganic & medicinal chemistry letters.

[138]  J. Moss,et al.  Interaction of phosphodiesterase 3A with brefeldin A-inhibited guanine nucleotide-exchange proteins BIG1 and BIG2 and effect on ARF1 activity , 2009, Proceedings of the National Academy of Sciences.

[139]  R. Kass,et al.  The Cardiac IKs Potassium Channel Macromolecular Complex Includes the Phosphodiesterase PDE4D3* , 2009, Journal of Biological Chemistry.

[140]  T. Eschenhagen,et al.  Capturing adenylyl cyclases as potential drug targets , 2009, Nature Reviews Drug Discovery.

[141]  Haiqing Zhao,et al.  Phosphodiesterase 1C is dispensable for rapid response termination of olfactory sensory neurons , 2009, Nature Neuroscience.

[142]  P. Schafer,et al.  Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. , 2009, Journal of medicinal chemistry.

[143]  T. Nakatsuka,et al.  ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. , 2009, Immunology letters.

[144]  D. Maurice,et al.  Distinct phosphodiesterase-4D variants integrate into protein kinase A-based signaling complexes in cardiac and vascular myocytes. , 2009, American journal of physiology. Heart and circulatory physiology.

[145]  Jennifer E. Chubb,et al.  DISC1, PDE4B, and NDE1 at the centrosome and synapse. , 2008, Biochemical and biophysical research communications.

[146]  L. Rassenti,et al.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia , 2008, Proceedings of the National Academy of Sciences.

[147]  Changsun Choi,et al.  The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. , 2008, The Journal of veterinary medical science.

[148]  G. Fain,et al.  Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q). , 2008, Investigative ophthalmology & visual science.

[149]  K. Black,et al.  PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model , 2008, Brain Research.

[150]  Hisham S. Elbatarny,et al.  Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions , 2008, Proceedings of the National Academy of Sciences.

[151]  A. Blokland,et al.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement , 2008, Psychopharmacology.

[152]  C. Teixeira,et al.  Vardenafil, but not sildenafil or tadalafil, has calcium‐channel blocking activity in rabbit isolated pulmonary artery and human washed platelets , 2008, British journal of pharmacology.

[153]  G. Bernardi,et al.  Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease , 2008, Neurobiology of Disease.

[154]  F. Menniti,et al.  PDE9A-MEDIATED REGULATION OF CGMP: IMPACT ON SYNAPTIC PLASTICITY , 2008, Schizophrenia Research.

[155]  S. Paciga,et al.  PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia , 2008, Schizophrenia Research.

[156]  C. Stratakis,et al.  Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. , 2008, The New England journal of medicine.

[157]  S. Rasmussen,et al.  Signaling from β1- and β2-adrenergic receptors is defined by differential interactions with PDE4 , 2008, The EMBO journal.

[158]  H. Ke,et al.  Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil , 2008, Molecular Pharmacology.

[159]  B. Zhu,et al.  Spectrin-anchored phosphodiesterase 4D4 restricts cAMP from disrupting microtubules and inducing endothelial cell gap formation , 2008, Journal of Cell Science.

[160]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[161]  H. Ke,et al.  Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. , 2007, The Biochemical journal.

[162]  J. Roder,et al.  Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness , 2007, The Journal of physiology.

[163]  P. Backx,et al.  PI3K&ggr; Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes , 2007, Circulation research.

[164]  J. Siuciak,et al.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme , 2007, Neuropharmacology.

[165]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[166]  Benjamin D. Sachs,et al.  p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway , 2007, The Journal of cell biology.

[167]  E. Degerman,et al.  Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. , 2007, The Biochemical journal.

[168]  John G. Sled,et al.  Behavioral Phenotypes of Disc1 Missense Mutations in Mice , 2007, Neuron.

[169]  J. Beavo,et al.  Differential Regulation of Endothelial Cell Permeability by cGMP via Phosphodiesterases 2 and 3 , 2007, Circulation research.

[170]  D. Maurice,et al.  Protein Kinase A Phosphorylation of Human Phosphodiesterase 3B Promotes 14-3-3 Protein Binding and Inhibits Phosphatase-catalyzed Inactivation* , 2007, Journal of Biological Chemistry.

[171]  H. Ke,et al.  Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. , 2007, Current topics in medicinal chemistry.

[172]  E. Degerman,et al.  Re-discovering PDE3 inhibitors--new opportunities for a long neglected target. , 2007, Current topics in medicinal chemistry.

[173]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[174]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases in Health and Disease , 2006 .

[175]  R. Cantor,et al.  Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.

[176]  M. Houslay,et al.  Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca2+ , 2006, Journal of Cell Science.

[177]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[178]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[179]  P. Epstein,et al.  Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. , 2006, Biochemical and biophysical research communications.

[180]  I. Bossis,et al.  A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia , 2006, Nature Genetics.

[181]  B. Winblad,et al.  The antidepressant and antiinflammatory effects of rolipram in the central nervous system. , 2006, CNS drug reviews.

[182]  T. Michaeli,et al.  PDE7A1, a cAMP-specific Phosphodiesterase, Inhibits cAMP-dependent Protein Kinase by a Direct Interaction with C* , 2006, Journal of Biological Chemistry.

[183]  D. Nagel,et al.  Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival , 2006, Circulation research.

[184]  H. Ke,et al.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. , 2006, Journal of medicinal chemistry.

[185]  K. Chung,et al.  Phosphodiesterase inhibitors in airways disease , 2006 .

[186]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[187]  T. Fahrig,et al.  Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line , 2005, Molecular Pharmacology.

[188]  V. Manganiello,et al.  Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium* , 2005, Journal of Biological Chemistry.

[189]  Jennifer E. Chubb,et al.  DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling , 2005, Science.

[190]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[191]  D. Campbell,et al.  Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. , 2005, The Biochemical journal.

[192]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[193]  C. Grines,et al.  Coronary Stent Restenosis in Patients Treated With Cilostazol , 2005, Circulation.

[194]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[195]  L. Langeberg,et al.  The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways , 2005, Nature.

[196]  S. Francis.  Phosphodiesterase 11 (PDE11): is it a player in human testicular function? , 2005, International Journal of Impotence Research.

[197]  A. Seftel.  3',5'-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues. , 2005, The Journal of urology.

[198]  S. Jin,et al.  Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages 1 , 2005, The Journal of Immunology.

[199]  J. Taylor,et al.  3′,5′-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues , 2005, International Journal of Impotence Research.

[200]  David T Manallack,et al.  The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. , 2005, Journal of medicinal chemistry.

[201]  Kam Y. J. Zhang,et al.  A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design , 2005, Nature Biotechnology.

[202]  M. Huber,et al.  Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors , 2005 .

[203]  Peng Wang,et al.  Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IkappaB proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[204]  M. Pruniaux,et al.  Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation1 , 2004, The Journal of Immunology.

[205]  Kam Y. J. Zhang,et al.  Structural basis for the activity of drugs that inhibit phosphodiesterases. , 2004, Structure.

[206]  A. Nicholson,et al.  Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes , 2004, Molecular Pharmacology.

[207]  J. Beavo,et al.  A-Kinase Anchoring Proteins Interact with Phosphodiesterases in T Lymphocyte Cell Lines1 , 2004, The Journal of Immunology.

[208]  J. Hurley,et al.  Leber congenital amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP phosphodiesterase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[209]  Kam Y. J. Zhang,et al.  A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.

[210]  Chengyu Liu,et al.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. , 2004, The Journal of clinical investigation.

[211]  K. McIntyre,et al.  Phosphodiesterase 7A-Deficient Mice Have Functional T Cells , 2003, The Journal of Immunology.

[212]  H. Ke,et al.  The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. , 2003, Biochemistry.

[213]  Mark Gurney,et al.  The gene encoding phosphodiesterase 4D confers risk of ischemic stroke , 2003, Nature Genetics.

[214]  Jerry Lanfear,et al.  Immunohistochemical localization of PDE10A in the rat brain , 2003, Brain Research.

[215]  G. Baillie,et al.  Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2* , 2003, Journal of Biological Chemistry.

[216]  M. Kietzmann,et al.  AWD 12–281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis , 2003, The Journal of pharmacy and pharmacology.

[217]  L. Favot,et al.  VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors , 2003, Thrombosis and Haemostasis.

[218]  R. Lefkowitz,et al.  Retraction for Baillie et al., β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[219]  T. Kohout,et al.  Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins , 2002, Science.

[220]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[221]  Yongge Liu,et al.  Comparison of the Effects of Cilostazol and Milrinone on cAMP-PDE Activity, Intracellular cAMP and Calcium in the Heart , 2002, Cardiovascular Drugs and Therapy.

[222]  A. Sahu,et al.  A phosphatidylinositol 3-kinase–phosphodiesterase 3B–cyclic AMP pathway in hypothalamic action of leptin on feeding , 2002, Nature Neuroscience.

[223]  S. Jin,et al.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[224]  D. Bers.  Cardiac excitation–contraction coupling , 2002, Nature.

[225]  S. Jin,et al.  Myomegalin Is a Novel Protein of the Golgi/Centrosome That Interacts with a Cyclic Nucleotide Phosphodiesterase* , 2001, The Journal of Biological Chemistry.

[226]  W. Kim,et al.  Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159 , 2000, Archives of pharmacal research.

[227]  S. Jin,et al.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[228]  M. Houslay,et al.  The unique N‐terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains , 1999, FEBS letters.

[229]  M. Houslay,et al.  The RACK1 Signaling Scaffold Protein Selectively Interacts with the cAMP-specific Phosphodiesterase PDE4D5 Isoform* , 1999, The Journal of Biological Chemistry.

[230]  M. Houslay,et al.  Association with the SRC Family Tyrosyl Kinase LYN Triggers a Conformational Change in the Catalytic Region of Human cAMP-specific Phosphodiesterase HSPDE4A4B , 1999, The Journal of Biological Chemistry.

[231]  P. D. del Nido,et al.  Idiopathic dilated cardiomyopathy: a superantigen-driven autoimmune disease. , 1998, Circulation.

[232]  M. Conti,et al.  Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors. , 1998, Human reproduction.

[233]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[234]  P. Rothwell,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[235]  R. Haslam,et al.  Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. , 1997, The Biochemical journal.

[236]  Xin Jiang,et al.  Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[237]  R Fischmeister,et al.  cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[238]  J. R. Carpenter,et al.  Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. , 1992, British journal of clinical pharmacology.

[239]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[240]  D. Bregman,et al.  Molecular characterization of bovine brain P75, a high affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II beta. , 1991, The Journal of biological chemistry.

[241]  J. Beavo,et al.  High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. , 1991, The Journal of biological chemistry.

[242]  R. Haslam,et al.  Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. , 1990, Molecular pharmacology.

[243]  D. Bregman,et al.  High affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II-B. Cloning, characterization, and expression of cDNAs for rat brain P150. , 1989, The Journal of biological chemistry.

[244]  C. Lugnier,et al.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. , 1986, Biochemical pharmacology.

[245]  J A Bristol,et al.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. , 1985, Journal of medicinal chemistry.

[246]  L. Brunton,et al.  Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. , 1983, The Journal of biological chemistry.

[247]  H. Wachtel,et al.  Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors , 1983, Neuropharmacology.

[248]  J. Hardman,et al.  Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. , 1980, Biochimica et biophysica acta.

[249]  J. N. Wells,et al.  Cyclic nucleotide phosphodiesterase activities of pig coronary arteries. , 1975, Biochimica et biophysica acta.

[250]  M. M. Appleman,et al.  CYCLIC NUCLEOTIDE PHOSPHODIESTERASE AND CYCLIC AMP * , 1971, Annals of the New York Academy of Sciences.

[251]  T. C. West,et al.  The potentiation of cardiac inotropic responses to norepinephrine by theophylline. , 1963, The Journal of pharmacology and experimental therapeutics.

[252]  E. Sutherland,et al.  Formation of a cyclic adenine ribonucleotide by tissue particles. , 1958, The Journal of biological chemistry.

[253]  Dong-mei Jin,et al.  Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. , 2012, Atherosclerosis.

[254]  N. Hanania,et al.  New bronchodilators. , 2012, Current opinion in pharmacology.

[255]  Anindita Das,et al.  Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. , 2011, Experimental and clinical cardiology.

[256]  H. Ke,et al.  Structural insight into the substrate specificity of phosphodiesterases. , 2011, Handbook of experimental pharmacology.

[257]  R. Newton,et al.  Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. , 2011, Handbook of experimental pharmacology.

[258]  M. Movsesian,et al.  Phosphodiesterase inhibition in heart failure. , 2011, Handbook of experimental pharmacology.

[259]  J. Kehler,et al.  PDE10A inhibitors: novel therapeutic drugs for schizophrenia. , 2011, Current pharmaceutical design.

[260]  A. Hatzelmann,et al.  Phosphodiesterase inhibitors: history of pharmacology. , 2011, Handbook of experimental pharmacology.

[261]  T. Dunkern,et al.  The GAF-tandem domain of phosphodiesterase 5 as a potential drug target. , 2011, Handbook of experimental pharmacology.

[262]  N. Brandon,et al.  Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals. , 2009, Progress in brain research.

[263]  P. Pohl,et al.  Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. , 2007, Journal of the American Society of Nephrology : JASN.

[264]  D. Marko,et al.  Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts , 2007, Cell Biochemistry and Biophysics.

[265]  H. Ke,et al.  Conformational variations of both PDE5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil , 2007 .

[266]  G. Baillie,et al.  Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Overview of PDEs and Their Regulation Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular Syste , 2007 .

[267]  M. Bajpai,et al.  AKAP3 Selectively Binds PDE4A Isoforms in Bovine Spermatozoa1 , 2006, Biology of reproduction.

[268]  D. Nagel,et al.  Role of Nuclear Ca 2 (cid:1) /Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival , 2006 .

[269]  Ph.D. Wolfgang Schaper M.D..  Dipyridamole, an Underestimated Vascular Protective Drug , 2005, Cardiovascular Drugs and Therapy.

[270]  Jonas JUREVICdIUS,et al.  cAMP compartmentation is responsible for a local activation of cardiac CaZ+ channels by ,8-adrenergic agonists , 2005 .

[271]  D. Campbell,et al.  Phosphodiesterase 3 A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser 428 , 2005 .

[272]  Susan S. Taylor,et al.  A genetically encoded, fluorescent indicator for cyclic AMP in living cells , 1999, Nature Cell Biology.

[273]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[274]  R. Rodeheffer,et al.  Effects of oral milrinone on mortality in severe chronic heart failure. Commentary , 1992 .

[275]  Retinitis pigmentosa,et al.  RETINITIS PIGMENTOSA , 1941, The Lancet.

[276]  L. Brunton,et al.  Functional compartmentation of cyclic AMP and protein kinase in heart. , 1981, Advances in cyclic nucleotide research.

[277]  P. Epstein,et al.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. , 1979, Advances in cyclic nucleotide research.

[278]  J. Beavo,et al.  Role of Ca 2 (cid:1) /Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy , 2009 .